Marco Zaccaria: The “Ghost” Fibroid That Can Disappear During Hysteroscopy
Marco Zaccaria, Global Product Manager at ESGE European Society Gynecology Endoscopy, shared a post on LinkedIn:
“A FIGO Type 3 myoma is a fibroid (located within the muscular wall of the uterus) that makes direct contact with the endometrium but does not protrude into the uterine cavity
It is called a ‘ghost’ because, due to the pressure exerted by the fluid used to distend the uterus during the examination, the lesion may temporarily ‘disappear’ from the surgeon’s view
Visible but not palpable: in many cases, the fibroid can be felt with surgical instruments or may slightly alter the uterine contour, but it does not protrude clearly into the cavity, making direct visual diagnosis very difficult
A potential minimally invasive treatment option is interstitial myolysis using microwave or radiofrequency thermal ablation, which replaces the initial slicing procedure (Step 1) to alter the tissue condition and facilitate a smoother enucleation (Step 2), as the intramural portion often migrates into the uterine cavity.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 8, 2026, 15:54Understanding HELLP Syndrome: A Life-Threatening Pregnancy Complication – Preeclampsia Foundation
-
Jul 8, 2026, 15:02FIGO Fistula Expert Advisory Group Celebrates Decade of Progress
-
Jul 8, 2026, 14:55UOG Journal Highlights Unusual Total Anomalous Pulmonary Venous Connection Case – ISUOG
-
Jul 8, 2026, 14:30Your Ovary Has a Story, We Take Time to Read It – Fertility Plus
-
Jul 8, 2026, 14:03Tom Holland: Excellent Talk Today from Joel Naftalin at the UK Fibroid Summit
-
Jul 8, 2026, 13:18Thank You All for Making this Yet Another Unforgettable Edition of Our Annual Meeting – ESHRE
-
Jul 8, 2026, 13:02Today Marks the Start of Group B Strep Awareness Week – RCOG
-
Jul 8, 2026, 12:03Jon Evans to Present Evolutionary Biology Research at International Spermatology Symposium – ChRS
-
Jul 8, 2026, 10:16Marco Zaccaria: Expert Discussions on Fibroid Thermoablation at ESHRE 2026